Thomas Lingelbach | President And Chief Executive Officer
Valneva

Thomas Lingelbach, President And Chief Executive Officer, Valneva

Following the Intercell-Vivalis merger, Thomas Lingelbach was appointed President & CEO of Valneva. He has been with Intercell since 2006, serving as COO until 2011 and since then as CEO. He has held a variety of positions of increasing international responsibility in his more than 20 years in the pharma and vaccine industry. He joined Intercell from Novartis Vaccine & Diagnostics as Managing Director Germany focusing on the integration with Chiron Vaccine where he served as Vice President Global Industrial Operations and Managing Director Chiron-Behring. Thomas Lingelbach holds a Master's degree in Engineering and complemented his education with a Business Administration program.

Appearances:



April 16 Day 2 - 10 Co-conferences @ 14:40

Towards a novel prophylactic vaccine for the prevention of Lyme disease: Development status and outlook

last published: 21/Mar/19 15:25 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071